GHK-Cu Dosage Guide: Reported Ranges, Reconstitution & Half-Life

GHK-Cu at a glance

What it is

GHK-Cu, the tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II)

Researched for

Skin remodeling, collagen synthesis, wound healing and hair-follicle research contexts

Commonly reported range

Topical formulations commonly 0.05-2%; injectable research examples around 1-2 mg per administration (no established human dose)

Route reported

Predominantly topical; subcutaneous injection is described in research/community settings

Reported frequency

Topical once or twice daily; injectable examples commonly daily or several times weekly

Reported cycle

Community examples of roughly 4-8 weeks, then a break

Plasma half-life

Short - GHK is cleared rapidly from plasma; no well-established human half-life for the copper complex

Regulatory status

Not an FDA-approved drug; GHK-Cu appears as a cosmetic ingredient. Injectable material is research use only

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

GHK is a tripeptide (glycyl-L-histidyl-L-lysine) found naturally in human plasma, saliva and urine, where its concentration is reported to decline substantially with age. It binds copper(II) with high affinity, and the resulting GHK-Cu complex is the form studied in most research. Published work describes GHK-Cu acting as a copper-delivery molecule that modulates the expression of a broad set of genes involved in tissue remodeling, and as a stimulator of collagen, elastin, glycosaminoglycan and proteoglycan synthesis by dermal fibroblasts. It is also reported to influence matrix metalloproteinases and their inhibitors, which together govern how the extracellular matrix is broken down and rebuilt, and to have antioxidant and anti-inflammatory activity in cell and animal models. Because copper is itself a required cofactor for enzymes such as lysyl oxidase, the peptide's copper-carrying role is central to the proposed mechanism rather than incidental to it.

Researched effects

In research settings GHK-Cu has been associated with increased collagen production, improved skin firmness and elasticity, reduced appearance of fine lines, faster wound closure in animal models, and effects on hair-follicle size in a small number of studies. The strongest human evidence is for topical cosmetic formulations measured on skin-appearance endpoints; injectable systemic use is far less studied in humans. These are reported research findings, not guaranteed outcomes, and results in studies varied between individuals. Nothing here is a promise of efficacy or a personal recommendation.

Dosage — reported ranges (overview)

The figures below are examples of what has been reported in cosmetic formulations and research/community settings, not a recommendation. Topical products are usually described by concentration rather than by dose, most commonly in the 0.05% to 2% range, applied once or twice daily. For the injectable research form, community-reported examples cluster around 1-2 mg per administration, often described as daily or several times weekly for a defined block of weeks. There is no established human dose, no regulatory dosing guidance, and no controlled trial defining a systemic dose. Copper is cumulative in the body, which is why sources consistently describe conservative amounts and defined breaks rather than continuous use.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

GHK-Cu is dosed in milligrams, so reconstitution is a concentration calculation. Add bacteriostatic water to the lyophilized vial and the concentration is the vial's total mg divided by the water volume in mL. On a U-100 insulin syringe, 100 units equals 1 mL, so units to draw = dose (mg) / concentration (mg/mL) x 100. Worked example: a 50 mg vial reconstituted with 2 mL of bacteriostatic water gives 25 mg/mL; a 2 mg example is then 2 / 25 = 0.08 mL, which is 8 units on a U-100 syringe. This is concentration math only, not a personal dose. GHK-Cu solutions are a distinctive blue; add water slowly down the vial wall and swirl gently rather than shaking.

This is concentration math, not a dose recommendation.

Injection / administration basics

Most GHK-Cu use described in the literature is topical, applied to clean skin as a serum or cream. Where injection is described in research and community settings it is subcutaneous with a small-gauge insulin syringe, using aseptic technique and site rotation; some sources describe localized subcutaneous administration near the area of interest. General handling concepts - sterile technique, site rotation, timing - are covered here as general information; the detailed workflow comes with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol; a qualified professional should guide any actual use.

Half-life & frequency rationale

Free GHK is cleared from plasma rapidly, on the order of minutes, and no well-established human plasma half-life has been published for the GHK-Cu complex administered systemically. Reported effects in tissue research are generally attributed to downstream signaling and matrix remodeling rather than to sustained plasma levels, which is why frequent or topical administration is the pattern described in most sources.

Stacking — overview

GHK-Cu is the component that turns the two-peptide Wolverine pairing (BPC-157 + TB-500) into GLOW, and GLOW plus KPV into KLOW - the two best-known pre-mixed repair blends, both of which contain GHK-Cu. It is also commonly paired with AHK-Cu in cosmetic and hair-research contexts. These reflect reported pairings, not recommendations, and no controlled trial has studied any of these combinations together.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Lyophilized (unreconstituted) vials are typically stored refrigerated and protected from light; the sealed powder is generally described as stable at room temperature for short periods before use.
• After reconstitution, keep refrigerated (about 2-8 C), protect from light, and use within a few weeks; do not freeze and avoid shaking. The blue colour is expected and reflects the copper complex.

Evidence File

GHK-Cu Evidence File: Three Registry Records, Twenty-Two Named Searches, Five Figures Traced to Origin

GHK-Cu is one of the most heavily marketed peptides in cosmetic science and one of the thinnest presences in the clinical trial registry. This file begins with a naming problem: the strings that carry this compound's drug-development record are not the strings anyone searches. It then prints every ClinicalTrials.gov and PubMed query that was run, reads each registered record field by field before making any statement about what has or has not been reported, and follows five of the numbers that circulate about this compound back to the exact sentence, table or database query where each one originated. Where a figure holds up, this file says so, and where a source cites the wrong paper for its own most-quoted line, this file names the paper it should have cited.

• The registry holds three GHK-Cu records; one gives GHK-Cu on its own.
• The 4,000-gene figure is 31.2% of 13,424 genes, computed in two cancer cell lines.
• The 136 ug/cm2 skin figure is one dataset the publisher says was printed twice.
• Searching PubMed for prezatide, this compound's INN, returns zero records.

Sourcing File

GHK-Cu Sourcing File: Five Substances, One Name, and the Copper Nobody Counts

Almost every sourcing question about this compound collapses into one question that no supplier page asks: which substance is in the vial. The three letters GHK-Cu are shared by several distinct registry entries with different formulas, different masses and different copper loads, and one of them contains no copper at all. This file resolves the identity numbers against the registries, states the masses in both the neutral and the protonated form so that a mass-spectrometry line can actually be checked, works the salt arithmetic all the way to milligrams in the vial, and then reads a certificate line by line to show where the contradiction surfaces.

• Five registry substances and five CAS numbers share the single name GHK-Cu.
• A 50 mg vial carries 7.91, 4.28, 3.68 or 0 mg of elemental copper.
• Molecular weight 340.4 on a GHK-Cu certificate is the copper-free peptide.
• PubChem lists GHK-Cu as a synonym of a copper-free compound, CID 73587.

Benefit & Outcome Review

GHK-Cu Outcome Review: Two Indexed Randomised Trials, and Where the Wrinkle Claim Came From

This review separates what has been measured in people from what has been measured in cells, rodents and databases, and it keeps the negative results in. It starts from an independent systematic review's own count of how many randomised trials of this compound exist, reads each human trial against its stated endpoints rather than its conclusion paragraph, and then follows the most familiar cosmetic claim back through the citation chain to the documents it actually rests on. Claim by claim, it separates results that are attributable to GHK-Cu from results that belong to a formulation, a device, a delivery vehicle or a control group, and it names the places where the compound's own review literature cites the wrong paper for its own most-repeated line.

• A PRISMA review to March 2026 counted 2 randomised trials of GHK-Cu alone.
• In 86 venous-ulcer patients, the copper tripeptide cream matched placebo.
• The cream wrinkle data traces to conference proceedings and a 2005 book chapter.
• No human study of GHK-Cu alone for hair growth was located here.

Guide FAQ

Quick answers about guide scope, access, and educational use context.